B-CELL NON HODGKIN LYMPHOMA

This study looks at whether a special health check-up for older adults (geriatric assessment) can help people aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. The check-up identifies weaknesses in physical function, thinkin…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or returning lymphoma will receive the treatment. The…

This study is for children and young people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments cure only about 30% of these patients and have severe side effects. The trial will test several new medicines, alone or with chemother…

This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma. The goal is to find safe doses and see if the drug can shrink tumors. About 91 participants will take part across multiple…

This study is testing a new drug called AZD0486, either alone or with other cancer drugs, in people with certain types of blood cancers like leukemia and lymphoma. The goal is to see if the drug is safe and works against the cancer. About 408 adults will take part in this early-p…

This early-phase study tests a new treatment made from cord blood cells that are engineered to find and attack cancer cells in people with B-cell non-Hodgkin lymphoma that has not responded to standard therapy. About 24 adults aged 18 to 75 will receive these special immune cells…

This early-phase study tests a new treatment called MC10029, which uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells. The therapy targets a protein called BAFFR found on certain blood cancer cells. The study includes up to…

This early-phase study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a special antibody that helps the immune system attack cancer cells. The main goals are to c…

This study tests a new type of CAR-T cell therapy for children and teens with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified t…

This study tests a drug called loncastuximab tesirine combined with other anti-cancer drugs in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. About 200 adults aged 18 and older …

This study tests a new drug called surovatamig in 240 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink or eliminate tumors. Participants receive the drug alone, and researchers …

This early-stage study tests a new drug, SAR448501, in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to check the drug's safety and find the best dose. Participants will receive the dr…

This study tests a new type of CAR T-cell therapy for adults with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy uses a patient's own immune cells that are specially trained to find and attack cancer cells. The main goals are to find the…

This study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to improve cancer remissi…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The study aims to find the safest…

This study tests whether giving a special immune cell treatment (CD19 CAR-T) right after a stem cell transplant can help people with a hard-to-treat type of lymphoma. It includes 16 adults whose lymphoma has come back or not responded to standard treatments. The main goal is to s…

This early-phase study tests a new CAR-T cell treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The main goals are to find a safe dose and see how well the treatment works. About 27 adults aged 18-75 will…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, blood cell counts, growth, and overall health over time. The goal is to understand the long-term safety of these treatments.